Related Experiment Videos
Management of hyperlipidemia in the elderly population: an evidence-based approach
1Department of Education, Eastern Virginia Medical School, Norfolk, VA, USA.
Insights
Lipid-lowering therapy, particularly statins, is effective for preventing coronary heart disease (CHD) in older adults. Estrogen replacement therapy is not recommended for secondary prevention of CHD in postmenopausal women.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Coronary heart disease (CHD) is a major health concern in individuals over 65.
- Elevated cholesterol levels significantly increase CHD risk in this demographic.
- Optimal strategies for CHD prevention in the elderly remain an area of focus.
Purpose of the Study:
- To evaluate the efficacy and safety of lipid-lowering therapies for CHD prevention in older adults.
- To examine the role of estrogen replacement therapy (ERT) in postmenopausal women with CHD.
Main Methods:
- Review of current clinical trial evidence on lipid-lowering agents, specifically HMG-CoA-reductase inhibitors.
- Analysis of data concerning estrogen replacement therapy and its impact on secondary CHD prevention.
Main Results:
- Lipid-lowering therapy, including statins, demonstrates effectiveness in reducing CHD morbidity and mortality in the elderly without significant adverse effects.
- Estrogen replacement therapy is not advised for postmenopausal women with existing CHD for secondary prevention.
Conclusions:
- Lipid-lowering treatment is recommended for individuals aged 65-75 with a history of CHD or at moderate-to-high risk.
- Estrogen replacement therapy should not be used for secondary CHD prevention in postmenopausal women based on current evidence.
Abstract:
Coronary heart disease (CHD) is the leading cause of morbidity and mortality in patients more than 65 years old. Within this population, elevated cholesterol levels are prevalent and associated with increased risk of CHD. Despite increasing emphasis on lipid-lowering treatment in the elderly population, questions remain regarding secondary and primary prevention of CHD. According to current clinical trial evidence, lipid-lowering therapy, specifically with HMG-CoA-reductase inhibitors, can reduce CHD morbidity and mortality without increased adverse effects in the elderly population. Lipid-lowering treatment should be considered for patients aged 65 to 75 years with a history of CHD or who are at moderate to high risk for CHD. Estrogen replacement therapy (ERT), which has also been shown to lower cholesterol levels, raises special considerations for postmenopausal women. However, recent findings suggest that postmenopausal women with a history of CHD should not be given estrogen solely for secondary prevention of CHD events.